Xcout Intel
Leyden Labs
Leyden Labs develops intranasal antibody-based nasal sprays designed to prevent respiratory virus infections directly at the nasal mucosa. The company's products aim to provide broad, self-administrable protection against various strains of viruses like influenza and COVID-19 to combat both current and future pandemic threats.
Subscribe to see Leyden Labs’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Leyden Labs at a glance
Leyden Labs is a biotechnology company headquartered in Netherlands. Its most recent funding round raised $44M in June 2026. Xcout tracks 18 named people at Leyden Labs, including Rosemary Tan (Chief Executive Officer).
Leyden Labs leadership
- Rosemary TanChief Executive Officer
- Marieke van der LansChief Financial Officer
- Clarissa KochChief Research Officer
- Jintanat AnanworanichChief Medical Officer
- Xavier MaesGeneral Counsel
- Koenraad Wiedhaupfounder and CEO
12 more named people on record for Leyden Labs, with roles, board committees and tenure — see the full roster →
Leyden Labs funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $44M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Leyden Labs news
Investors
Leyden Labs competitors
A few of Leyden Labs's closest competitors — see the full list of competitors and alternatives →
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
EnGen Bio, LLC is a biotechnology company developing therapies and vaccines designed to provide lifetime immunity against Type A influenza in both humans and animals. The company targets a novel epitope on the flu virus's M1 matrix protein to elicit broadly neutralizing antibody responses. It serves the human healthcare, veterinary, and pharmaceutical sectors.
Calder Biosciences Inc. is a nano-scale molecular engineering company founded in 2018 that develops next-generation conformationally-stabilized universal influenza vaccines and other biologics.
Memo Therapeutics AG (MTx) is a late-stage biotech company focused on developing best-in-class therapeutic antibodies. The company aims to transform the lives of patients with viral infections and has shown encouraging Phase II data.
Xanadu Bio, Inc. is a biotechnology company that develops next-generation polymer nanoparticle delivery platforms for mRNA and other nucleic acid-based therapies. Utilizing its proprietary poly(amine-co-ester) (PACE) polymer technology, the company creates tunable, organ-specific treatments for oncology and immunology, as well as intranasal vaccines for viral respiratory pathogens.
BlueWillow Biologics, Inc. is a privately held clinical-stage biopharmaceutical company located in Ann Arbor, Michigan. The company specializes in the development of proprietary intranasal vaccines and immune-modulating technologies.
Get Leyden Labs's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Leyden Labs in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access